Extension Study for Patients Continuing Venetoclax Treatment from Previous Trials
Sponsor: AbbVie
Sponsor score: 60
ClinicalTrials ID:NCT03844048
This study allows patients who have been part of a previous venetoclax trial to continue receiving the medication and helps researchers gather long-term safety information.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The goal of this extension study is to continue providing the medication venetoclax to patients who have been part of earlier trials and are still benefiting from it. Researchers will also collect information on the long-term safety of the drug for these patients.
Eligibility Criteria
Inclusion Criteria
- You must have been part of a previous venetoclax study and still be benefiting from the treatment.
- If you are male, you must agree not to donate sperm during the study.
- If you are female, you must not be pregnant or breastfeeding.
Exclusion Criteria
- None.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| University of Arizona Cancer Center - Tucson /ID# 210548 | 85724 | Tucson | Arizona |
| UCLA Santa Monica Hematology Oncology /ID# 210551 | 90095 | Los Angeles | California |
| Ingalls Memorial Hosp /ID# 210553 | 60426 | Harvey | Illinois |
| Dana-Farber Cancer Institute /ID# 215360 | 02215 | Boston | Massachusetts |
| University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 231132 | 48109 | Ann Arbor | Michigan |
| Dartmouth-Hitchcock Medical Center /ID# 210555 | 03756 | Lebanon | New Hampshire |
| Swedish Cancer Institute /ID# 213120 | 98104-3588 | Seattle | Washington |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.